Improving the function of arteriovenous fistulas for dialysis patients
Development of a Treatment to Improve Arteriovenous Fistula Function
This study is testing a new treatment to help improve the function of arteriovenous fistulas (AVFs) for people on hemodialysis, aiming to prevent problems that can cause these important access points to fail.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pavaj Vascular Corporation NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10919089 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment to enhance the function of arteriovenous fistulas (AVFs), which are crucial for patients undergoing hemodialysis. The study aims to address the common issue of venous stenosis, a condition that leads to AVF failure and affects many patients with end-stage kidney disease. By utilizing a novel therapy that targets the biological mechanisms behind venous stenosis, the research seeks to improve the longevity and effectiveness of AVFs, ultimately benefiting patients who rely on these for dialysis. The approach involves the use of nanoparticles to deliver therapeutic agents directly to the site of the AVF, potentially offering a non-invasive solution to a significant problem in dialysis care.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with end-stage kidney disease who require hemodialysis and have arteriovenous fistulas.
Not a fit: Patients who do not require hemodialysis or have alternative vascular access methods may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the longevity and functionality of arteriovenous fistulas, enhancing the quality of life for patients requiring hemodialysis.
How similar studies have performed: Other research has shown promise in using targeted therapies to improve vascular access outcomes, suggesting that this approach could be effective.
Where this research is happening
Rochester, United States
- Pavaj Vascular Corporation — Rochester, United States (Active)
Researchers
- Principal investigator: Miller, Aaron — Pavaj Vascular Corporation
- Study coordinator: Miller, Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.